Iradimed PE ratio IRMD
Share price divided by earnings per share over the last twelve months, since 2015.
- Today, Oct 23, 2026
- 47.9×
- 10-year median
- 41.4×
- Against its 10-year history
- 59th
- percentile: 0 is its lowest day, 100 its highest
- 10-year range
- 12.0× to 431×
- Peer median
- 30.1×
Iradimed's PE ratio is 47.9× as of Oct 23, 2026: a share price of $85.82 against $1.79 of earnings per share over the last twelve months.
That is above its ten-year median of 41.4×, close to the middle of its last ten years.
Over that time it ranged from 12.0× in Feb 2017 to 431× in Jul 2021.
The median for 10 medical instruments and supplies stocks of a similar size is 30.1×.
PE ratio over time
The dashed line is the 10-year median and the shaded band the middle half of its days.
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 47.9× | 45.9× | 62.8× |
| 2025 | 59.1× | 33.0× | 59.1× |
| 2024 | 37.4× | 29.8× | 38.7× |
| 2023 | 36.8× | 28.8× | 46.4× |
| 2022 | 27.2× | 26.9× | 103× |
| 2021 | 96.3× | 69.7× | 431× |
| 2020 | 71.3× | 20.6× | 77.8× |
| 2019 | 37.3× | 28.1× | 70.3× |
| 2018 | 57.8× | 57.4× | 365× |
| 2017 | 117× | 12.0× | 117× |
| 2016 | 16.1× | 13.3× | 55.8× |
| 2015 | 63.7× | 59.0× | 103× |
Against its peers
Companies in Medical - Instruments & Supplies nearest Iradimed's size, closest first, today.
| Company | PE ratio |
|---|---|
| IRMDIradimed | 47.9× |
| STAAStaar Surgical | 323× |
| BVSBioventus | 19.4× |
| CDRECadre | 37.0× |
| EYENational Vision | 30.6× |
| MOVMovado | 17.5× |
| LMATLemaitre Vascular | 29.6× |
| INSPInspire Medical Systems | 15.4× |
| MDXGMimedx | 97.8× |
| TCMDTactile Systems Technology | 21.9× |
| UFPTUFP Technologies | 31.9× |
| Peer median | 30.1× |
Where Iradimed ranks
What the PE ratio tells you
Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.
Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.
More on Iradimed
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.